| Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants | Frontiers in pharmacology |  | | 2026 | 12 | 20 |
|
| Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling | Clinical pharmacokinetics | | | 2025 | 71 | 170 |
|
| The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID-19 Patients : A Physiologically Based Pharmacokinetic Modeling Study | Clinical pharmacology and therapeutics | | | 2025 | 77 | 504 |
|
| Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban | British journal of clinical pharmacology |  | | 2025 | 88 | 1 |
|
| Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side | CPT: pharmacometrics & systems pharmacology | | | 2023 | 149 | 544 |
|
| Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study | CPT: pharmacometrics & systems pharmacology | | | 2023 | 137 | 481 |
|
| Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation | Clinical pharmacology and therapeutics | | | 2022 | 168 | 327 |
|
| Computer-based strategies to improve safety and riskmanagement of antithrombotic therapies in hospitalizedpatients | | | | 2022 | 239 | 0 |
|
| Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians | The American journal of medicine | | | 2021 | 182 | 0 |
|
